[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Deng HJ, Wei ZG, Zhen L, Li GX, Uang XC, Qing SH: [Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):295-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer].
  • OBJECTIVE: To evaluate the clinical effect of intraoperative and early postoperative continuous hyperthermic pertioneal perfusion chemotherapy (CHPPC) for gastric cancer.
  • METHODS: Eight-five patients with gastric cancer were randomized into therapeutic group with perioperative CHPPC combined with intravenous chemotherapy (n=44) and control group with intravenous chemotherapy only (n=41).
  • The recurrence rate and distant metastasis rates in the therapeutic group were significantly lower than those in the control group (20.45% vs 43.90%, and 15.90% vs 39.02%, P<0.05).
  • The 1- and 3-year survival rates in the therapeutic group were significantly higher than those in the control group (90.90% vs 78.05%, and 59.09% vs 34.15%, P<0.05).
  • CONCLUSION: Perioperative CHPPC for gastric cancer is safe and feasible, and can reduce the recurrence rate, distant metastasis rate and improve the survival for gastric cancer patient after operation.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Intraperitoneal. Intraoperative Period. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246304.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


2. Uesato M, Nabeya Y, Miyazaki S, Aoki T, Akai T, Shuto K, Tanizawa T, Miyazaki M, Matsubara H: Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach. World J Gastrointest Endosc; 2010 Oct 16;2(10):349-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach.
  • We report on a case of a 74 year old man who was diagnosed with a recurrence of non-invasive carcinoma of intraductal papillary mucinous neoplasm (non-invasive IPMN) by postoperative gastroscopy (GS).
  • A histopathological study revealed non-invasive adenocarcinoma.
  • Later, the GS showed the elevated lesion with mucin hypersecretion in the remnant stomach.
  • We diagnosed a recurrence of IPMN and administered chemotherapy again.
  • It should be remembered that the elevated lesion of the remnant stomach is considered as one of the recurrent patterns of IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160585.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999103
  • [Keywords] NOTNLM ; Endoscopy / Fistula / Intraductal papillary mucinous neoplasm / Recurrence / Stomach
  •  go-up   go-down


3. Borgoño CA, Fracchioli S, Yousef GM, Rigault de la Longrais IA, Luo LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, Diamandis EP, Katsaros D: Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer; 2003 Sep 10;106(4):605-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
  • Recently, we developed a highly sensitive and specific immunoassay for hK11 and found that this protease is expressed in the prostate, stomach and trachea as well as in amniotic fluid and milk of lactating women.
  • An optimal cutoff value of 0.54 ng/mg was selected to categorize tumors as hK11-positive or -negative. hK11-positive tumors were more frequently associated with early stage (Stage I/II) disease, pre-/peri-menopausal status and patients who exhibited complete or partial response to chemotherapy (p < 0.05).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Disease Progression. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12845660.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R1CA93568-O1A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


Advertisement
4. Ha MW, Ma R, Shun LP, Gong YH, Yuan Y: Effects of allitridi on cell cycle arrest of human gastric cancer cells. World J Gastroenterol; 2005 Sep 21;11(35):5433-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of allitridi on cell cycle arrest of human gastric cancer cells.
  • AIM: To determine the effect of allitridi on cell cycle of human gastric cancer (HGC) cell lines MGC803 and SGC7901 and its possible mechanism.
  • When cells were treated with allitridi at the concentration of 6 microg/mL, cell mitotic index was much higher (P = 0.003) than that of control group, indicating that allitridi could cause gastric cancer cell arrest in M phase.
  • Besides, the expression levels of p21(WAF1) gene of MGC803 cells and p21(WAF1) gene of SGC7901 cells were remarkably upregulated after treatment.
  • CONCLUSION: Allitridi can cause gastric cancer cell arrest in M phase, and this may be one of the mechanisms for inhibiting cell proliferation.
  • This study provides experimental data for clinical use of allitridi in the treatment of gastric carcinoma.
  • [MeSH-major] Allyl Compounds / pharmacology. Antineoplastic Agents / pharmacology. Stomach Neoplasms / drug therapy. Sulfides / pharmacology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Base Sequence. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA, Neoplasm / genetics. Garlic. Humans. Microscopy, Electron

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222732.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Allyl Compounds; 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA, Neoplasm; 0 / Sulfides; 0ZO1U5A3XX / diallyl trisulfide
  • [Other-IDs] NLM/ PMC4320349
  •  go-up   go-down


5. Pandey M, Kumar V, Shukla M, Kumar M: Thyroid swelling in a 32-year-old male. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine-needle aspiration cytology from the thyroid swelling revealed deposits from the mucinous adenocarcinoma.
  • The further diagnostic and metastatic work-up identified a diffuse carcinoma of the stomach as the primary site with liver as secondary and retroperitoneal lymph nodes having mucinous deposits with associated Peutz-Jeghers polyposis.
  • This is the first report in the English literature of intrathyroidal metastasis from carcinoma of the stomach with Peutz-Jeghers polyposis presenting primarily as a thyroid swelling.
  • Preoperative diagnosis, proper evaluation and high degree of suspicion may avoid unnecessary thyroidectomy and effective palliation can be achieved with chemotherapy in view of disseminated disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2885-8 [19031929.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):127-35 [9916927.001]
  • (PMID = 21686341.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028274
  •  go-up   go-down


6. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of 980 patients with gastric cancer after surgical resection.
  • BACKGROUND AND OBJECTIVE: Although surgery is the only possible means to cure gastric cancer, the prognosis is often discrepant.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • This study aimed to use this new edition staging system to investigate the prognostic factors for gastric cancer.
  • METHODS: The clinicopathologic data of 980 patients with gastric cancer treated by surgical resection in our hospital between January 2000 and December 2006 were analyzed retrospectively.
  • In both univariate analysis and Cox multivariate analysis, age, tumor site, tumor size, histological type, resection type, radical resection, lymphatic/venous invasion, depth of invasion, nodal status, metastasis, retrieved lymph nodes, metastatic lymph node ratio, and adjuvant chemotherapy were prognostic factors with these patients.
  • CONCLUSION: Compared with the 6th edition system, the new edition of TNM staging system for gastric cancer can accurately predict the survival after operation.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Bae JM, Kim SW, Kim SW, Song SK: [Metachronous four primary malignancies in gastro-intestinal tract]. Korean J Gastroenterol; 2009 Jun;53(6):373-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, multiple primary malignancies are considered to increase due to improved survival rate of cancer patients, advanced diagnostic tools, and increased use of chemotherapy and radiotherapy.
  • Recently, we experienced a 70 year-old male who was diagnosed with metachronous four primary malignancies in rectum, ascending colon, stomach, and ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Gastrointestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Humans. Male. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556845.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


8. Mauron H, Streuli R: [Anemia, subcutaneous bleeding and weight loss. Disseminated metastasizing, mucinous adenocarcinoma of the stomach]. Praxis (Bern 1994); 2000 Sep 28;89(39):1568-72
MedlinePlus Health Information. consumer health - Weight Control.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anemia, subcutaneous bleeding and weight loss. Disseminated metastasizing, mucinous adenocarcinoma of the stomach].
  • [Transliterated title] Anämie, Suffusionen und Gewichtsverlust. Disseminiert metastasierendes, schleimbildendes Adenokarzinom des Magens.
  • The bone marrow examination was characterized by erythroid hyperplasia and an invasion by mucin-producing adenocarcinoma cells.
  • Upper endoscopy detected a small hiatal hernia with mucosal erosions between esophagus and stomach.
  • The histology of the mucosal biopsy identified a poorly differentiated mucin-producing adenocarcinoma with portions of signet-ring cells.
  • We diagnosed a disseminated, mucin-producing adenocarcinoma of the stomach, associated with microangiopathic hemolytic anemia.
  • In spite of rapidly begun chemotherapy with adriamycin and daily blood transfusions the woman died after four weeks.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Anemia, Hemolytic / etiology. Bone Marrow Neoplasms / secondary. Purpura / etiology. Stomach Neoplasms / pathology. Weight Loss / physiology
  • [MeSH-minor] Aged. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068511.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


9. Mokuno Y, Katayama M, Ogura Y, Kimura K, Koh K: Long-term survival after resection of metachronous bilateral adrenal metastases of mucinous gastric carcinoma: report of a case. Surg Today; 2006;36(6):554-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after resection of metachronous bilateral adrenal metastases of mucinous gastric carcinoma: report of a case.
  • We report a case of metachronous bilateral adrenal metastases from mucinous adenocarcinoma of the stomach.
  • A 68-year-old man who had undergone surgery for advanced gastric cancer 5 months earlier had a follow-up computed tomography (CT) scan, which showed a right adrenal tumor.
  • We performed a right adrenalectomy, and histopathological examination revealed a mucinous adenocarcinoma with features consistent with those of gastric cancer.
  • Chemotherapy had no apparent effect, and left adrenalectomy was performed 65 months after the right adrenalectomy.
  • Histopathological examination also revealed a metastasis from gastric cancer.
  • This case suggests that resection of adrenal metastasis from gastric cancer is an effective treatment option that may prolong survival in selected patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adrenal Gland Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adrenalectomy. Aged. Humans. Male. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):389-94 [9445197.001]
  • [Cites] Gan No Rinsho. 1989 Nov;35(14):1699-704 [2687502.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):95-101 [11849252.001]
  • [Cites] Urol Int. 2001;67(1):113-6 [11464135.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):95-112 [11809539.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):552-7 [6733685.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1191-6 [14654476.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):181-7 [10853037.001]
  • [Cites] Chest. 1997 Sep;112(3):848-50 [9315827.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):455-61 [12099659.001]
  • [Cites] Surgery. 1991 Feb;109 (2):127-31 [1992544.001]
  • [Cites] Surg Gynecol Obstet. 1977 Jul;145(1):41-8 [877823.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):528-31 [8665251.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Oct;13(5):328-33 [14571170.001]
  • [Cites] Surgery. 2001 Dec;130(6):1060-7 [11742339.001]
  • (PMID = 16715429.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • Two randomized phase III studies have shown improved survival for patients with induction chemotherapy followed by surgery compared with surgery alone.
  • It is generally accepted that patients who respond to induction therapy have a significantly improved survival compared with that in nonresponding patients.
  • In adenocarcinomas of the esophagogastric junction (AEG), fluorodeoxyglucose-positron emission tomography (FDG-PET) prospectively was established as a surrogate predicting response and prognosis.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • These findings are an important step forward in the tailoring of multimodal treatment in accordance with tumor biology.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.
  • Treatment concepts such as immediate resection after only 2 weeks of induction therapy with or without adjuvant treatment could be considered in metabolic nonresponders, or modified chemotherapy regimens, possibly including biologically targeted drugs, could be considered in those with FDG-nonavid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy / methods. Positron-Emission Tomography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Disease Progression. Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


11. Dong NN, Wang MY, Zhang Q, Liu ZF: [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. Ai Zheng; 2009 Apr;28(4):412-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
  • BACKGROUND AND OBJECTIVE: Combination therapy of oxaliplatin and capecitabine has certain effects on advanced gastric cancer (AGC).
  • This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients.
  • METHODS: Thirty-three chemotherapy-naive patients with AGC were entered into this study.
  • RESULTS: Thirty-three patients completed 159 cycles of chemotherapy with a median number of five cycles.
  • At a mean follow-up of 10.5 months, the median time to progression and overall survival were 5.9 (95% CI: 4.7-7.1) and 10.4 months (95% CI: 7.9-12.9), respectively.
  • CONCLUSION: XELOX is an effective and well-tolerated first-line chemotherapy regimen for patients with AGC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diarrhea / chemically induced. Disease Progression. Female. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622303.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


12. Hamada M, Tsuji A, Iwata J, Nishioka Y, Ozaki K, Shima Y, Horimi T: Neoadjuvant chemotherapy with S-1 and surgical resection for a mucinous gastric cancer with peritoneal dissemination. Gastric Cancer; 2005;8(1):50-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with S-1 and surgical resection for a mucinous gastric cancer with peritoneal dissemination.
  • We herein report the case of a patient with mucinous gastric carcinoma with peritoneal dissemination that disappeared after neoadjuvant chemotherapy with S-1 alone.
  • A 60-year old man was referred to our hospital because of an advanced gastric cancer, detected by upper gastrointestinal endoscopy at another hospital.
  • Two courses of neoadjuvant chemotherapy with S-1 were administered, at 120 mg/day for 28 days, as one course.
  • His final diagnosis was gastric carcinoma, MLU, type 3, T2(SS), P0, H0, M0, N3, CY0, stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Gastrectomy. Humans. Lymph Node Excision. Male. Middle Aged. Neoadjuvant Therapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747176.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Ishiguro A, Munakata M, Shitara K, Kasai M, Sakata Y: [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1457-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].
  • A 74-year-old man was revealed to have type 3 gastric cancer with lymph-node metastasis in the third group (N 3) and liver metastasis (H 1).
  • Since we regarded a curative operation as impossible, we started preoperative chemotherapy using TS-1 plus irinotecan hydrochloride (CPT-11) on the premise that we would perform surgical cytoreduction after the chemotherapy.
  • After two courses of chemotherapy, both the primary lesion and the liver metastasis were reduced in size, and the paraaortic lymph-nodes disappeared.
  • Subsequently, a distal gastrectomy (D 0, curability C) was performed.
  • The patient has been receiving postoperative chemotherapy using TS-1 and paclitaxel as an outpatient for 2.3 years.
  • Although there is not enough evidence to support the benefit of surgical cytoreduction, chemotherapy combined with surgical cytoreduction would improve the survival time without deterioration of quality of life (QOL) in patients with advanced gastric cancer.
  • This combined therapy should be considered as one of the promising strategies for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Quality of Life. Survivors. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033237.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Zhang J, Xiao Y, Lu M, Li J, Zhang XD, Li Y, Shen L: [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):312-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
  • OBJECTIVE: To evaluate the toxicity and efficacy of capecitabine-based chemotherapy in the treatment of advanced gastric cancer.
  • METHODS: 104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept.
  • The median cycles of treatment were 3 cycles.
  • The median overall survival and the median time to progression were 8.5 months and 5.2 months, respectively.
  • For the first-line chemotherapy, ORR was 40.0%, disease control rate was 76.7%; the median overall survival in all patients and in the patients with first-line chemotherapy of capecitabine plus paclitaxel were 10.9 months and 12.8 months, respectively.
  • CONCLUSION: The capecitabine-based chemotherapy was effective and tolerable.
  • The patients with KPS < 80 may choose capecitabine alone for the chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Capecitabine. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Remission Induction. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Vomiting / chemically induced. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615292.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Nakamura Y, Yumiba T, Yamasaki Y, Momiyama T, Ito A, Akamaru Y, Sugimoto Y, Tamaoka N, Beppu N, Watanabe Y, Ohno K, Kasugai T: [Two cases of stage IV gastric cancer responding to chemotherapy with S-1 or UFT]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1463-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of stage IV gastric cancer responding to chemotherapy with S-1 or UFT].
  • We report patients with advanced Stage IV gastric cancer responding to chemotherapy with S-1 or UFT.
  • Case 1: The patient was a 59-year-old man with Stage IV gastric cancer because of CY 1.
  • After surgery, chemotherapy with S-1 (100 mg/body/day) was performed for one year and 11 months.
  • Case 2: The patient was a 68-year-old woman with Stage IV gastric cancer because of P 1.
  • We considered that the longterm survival of such patients is attributable to chemotherapy with S-1 or UFT.
  • The OPRT activity of the two cases was high, so chemotherapy with S-1 or UFT was thought to be effective for them.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Female. Humans. Male. Middle Aged. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876147.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


16. Zhang J, He XH, Xie XY, Hu X, He C: The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer. J Int Med Res; 2010 Mar-Apr;38(2):423-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer.
  • This study was designed to investigate the relationship between serum p53, tissue p53 and tissue permeability glycoprotein (P-gp) levels in gastric cancer.
  • Serum levels of p53 were detected by enzyme-linked immunosorbent assay, and tissue p53 and P-gp levels were analysed by immunohistochemistry.
  • In total, 63.0% of gastric cancer tissue samples tested positive for P-gp and 58.7% of samples tested positive for p53.
  • Tissue P-gp immunoreactivity was significantly correlated with tissue p53 immunoreactivity, and both tissue p53 and P-gp immunoreactivity were significantly correlated to the degree of cancer cell differentiation.
  • The percentage of gastric cancer patients with serum positive for p53 was 36.2%, which was significantly higher than the rate in non-cancerous gastric disease patients.
  • Serum p53 was significantly correlated to tissue p53 and tissue P-gp, inferring that the presence of p53 in the serum could indicate the status of tissue p53 and P-gp.
  • This could, therefore, be useful for screening for the most appropriate (lowest toxicity and highest effectiveness) drugs to use ahead of (neo)-adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Stomach Neoplasms / blood. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / blood. Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Case-Control Studies. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. P-Glycoprotein / blood. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515556.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, Song SA, Jiang T: [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. Zhonghua Zhong Liu Za Zhi; 2010 Jul;32(7):515-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
  • OBJECTIVE: To evaluate the association between the polymorphisms of excision repair cross complementation group 1 (ERCC1), X-ray repair cross complementing 1 (XRCC1), glutathione S-transferase Pi 1 (GSTP1) and the survival of advanced gastric cancer patients treated with oxaliplatin-based combination chemotherapy.
  • METHODS: Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated.
  • Peripheral venous blood was taken before chemotherapy.
  • The genetic polymorphisms were detected by real-time PCR assay.
  • The association between time to progression, overall survival and the polymorphisms was analyzed.
  • RESULTS: The median time to progression of the 85 cases was 5.3 months, and the median overall survival was 8.0 months.
  • CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / genetics. Endonucleases / genetics. Glutathione S-Transferase pi / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Disease Progression. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Polymorphism, Genetic. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Organoplatinum Compounds; 0 / X-ray repair cross complementing protein 1; 04ZR38536J / oxaliplatin; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Kimura H, Koyama F: [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL]. Gan To Kagaku Ryoho; 2006 Feb;33(2):251-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
  • Upper GI endoscopy revealed type 3 gastric cancer from the anglus to the cardia.
  • We performed systemic chemotherapy of TS-1, CDDP and peritoneal infusion of docetaxel on the nonresected gastric cancer with peritoneal dissemination.
  • The patient clinically achieved good QOL by this method, which was very effective for nonresected gastric cancer with peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cardia. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Quality of Life. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484867.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Matsubara T, Yoshizawa Y, Sasaya S, Nemoto H, Aita K, Goto T, Shirahata A, Sanada Y: [Case study--an elderly patient with Stage IV advanced gastric cancer achieved good performance status (PS) without subjective symptoms for more than two years by chemotherapy]. Gan To Kagaku Ryoho; 2006 Mar;33(3):381-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case study--an elderly patient with Stage IV advanced gastric cancer achieved good performance status (PS) without subjective symptoms for more than two years by chemotherapy].
  • An 83-year-old male with Stage IV gastric cancer of performance status 1 (PS 1) was treated with fluoropyrimidine (TS-1) since January 2003 in our department.
  • We administered 11 four-week cycles, each with a two-week drug-free washout period, and six two-week cycles, each with a two-week drug free washout period.
  • The first cycle of chemotherapy ameliorated the subjective symptoms; the level of a tumor marker then returned to normal, and the ascites disappeared.
  • As second-line chemotherapy, we initiated weekly administration of paclitaxel (PTX).
  • Due to the patient's age and high PS level (PS 2) at the time of intervention, we utilized a reduced dose of 70 mg/body/dose.
  • After a short premedication period, the patient was administered PTX intravenously for one hour once a week for three weeks, then given a one-week drug-free washout period (one cycle).
  • Throughout the treatment period, we did not observe any significant adverse events (grade 2 or higher).
  • Treatment achieved a favorable PS level.
  • To design an effective chemotherapy regimen for elderly patients, it is important to establish an effective dose and dosing method based on the patient's chronologic age and a thorough evaluation of the patient's systemic conditions, including the PS level.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Humans. Male. Neoplasm Staging. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Prognosis. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Meguro E, Kaizuka H, Inaba T, Irinoda T, Hayakawa Y, Okada S, Yamaguchi S, Wakabayashi J: [A case of advanced gastric cancer which became operable after chemotherapy with combination of TS-1/CDDP and in which complete disappearance of liver metastasis was histopathologically confirmed]. Gan To Kagaku Ryoho; 2003 Jun;30(6):863-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer which became operable after chemotherapy with combination of TS-1/CDDP and in which complete disappearance of liver metastasis was histopathologically confirmed].
  • We encountered a patient in whom TS-1/cisplatin (CDDP) combination chemotherapy was effective.
  • Based on upper GI endoscopy and abdominal CT, type 1 gastric cancer associated with liver and abdominal lymph node metastases was diagnosed.
  • The cancer was judged to be inoperable, and chemotherapy with a combination of TS-1 and CDDP was initiated.
  • One course of treatment consisted of administration of 120 mg/day of TS-1 for 21 days followed by 14 days of withdrawal, and administration of 100 mg/body/day of CDDP on day 8 (80 mg/body/day in the second course).
  • After two courses of treatment, the primary lesion and the liver and lymph node metastatic lesions decreased in size (reduction ratios were 42.3%, 90.5% and 85.2%, respectively).
  • The only adverse event of Grade 2 or more severity observed during drug administration was anorexia.
  • TS-1/CDDP therapy is believed to provide effective treatment against liver metastasis and lymph node metastasis of gastric cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Hepatectomy. Humans. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Splenectomy. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852358.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Baldus SE, Mönig SP, Schneider PM, Hölscher AH, Dienes HP: [Adenocarcinoma of the stomach with heterotopic ossification. Case report and discussion of the pathogenesis]. Pathologe; 2002 Mar;23(2):156-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the stomach with heterotopic ossification. Case report and discussion of the pathogenesis].
  • [Transliterated title] Adenokarzinom des Magens mit heterotoper Ossifikation. Fallbericht und Diskussion der Pathogenese.
  • Heterotopic ossification of gastric adenocarcinomas is very rarely observed in humans.
  • We describe the case of a 70-year-old patient with an extended, initially spleen-infiltrating tubular adenocarcinoma of the stomach with a mucinous component, heterotopic ossifications and pronounced regressive alterations after neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12001533.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] GER
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Iizuka T, Hoshihara Y, Hoteya O, Yamamoto T, Yahagi N, Udagawa H: [A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration]. Gan To Kagaku Ryoho; 2006 May;33(5):659-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration].
  • A 74-year-old man was suffering from Borrmann type 2 advanced gastric cancer with abdominal lymph node metastases and multiple lung metastases.
  • He started to undergo outpatient treatment with oral administration of TS-1.
  • But pyloric stenosis was found after 6 courses of TS-1 chemotherapy, so he underwent palliative distal gastrectomy.
  • TS-1 chemotherapy was continued afterwards, however obstructive jaundice was found.
  • So combination chemotherapy of CPT-11 60 mg/m(2)and CDDP 30 mg/m(2)biweekly was selected as a second-line therapy after PTCD.
  • Thus, combination CPT-11 and CDDP therapy could well be a new candidate for a second-line chemotherapy in outpatients.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Jaundice, Obstructive / drug therapy. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drainage. Drug Administration Schedule. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685167.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Qu QL, Zhang YG, Yang LZ, Sun L: [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 Apr;28(4):257-60
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma].
  • OBJECTIVE: To prepare a new dosage formulation of activated carbon nanoparticles adsorbing mitomycin C (MMC-ACNP) and evaluate the beneficial effects of intraperitoneally applied MMC-ACNP as a drug delivery system for lymphatic targeting in preventing metastasis and recurrence of gastric cancer.
  • An experiment on nude mice model with transplanted human gastric cancer in 6 groups was completed to assess the effects of drugs on intra-abdominal carcinomatosis.
  • Fine activated carbon particles adsorbing MMC entered the nuclei of tumor cells, so that the effects of the anticancer drug were reinforced.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Charcoal / administration & dosage. Mitomycin / administration & dosage. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Animals. Drug Carriers. Drug Delivery Systems. Female. Humans. Injections, Intraperitoneal. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Nanoparticles. Neoplasm Transplantation. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ACTIVATED CHARCOAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875622.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 16291-96-6 / Charcoal; 50SG953SK6 / Mitomycin
  •  go-up   go-down


24. Zhan YQ, Sun XW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Ai Zheng; 2005 May;24(5):596-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
  • BACKGROUND & OBJECTIVE: Whether received radical operation is an important prognostic factor of gastric carcinoma.
  • This study was to investigate prognostic factors of gastric carcinoma.
  • METHODS: Clinical data of 405 patients with gastric carcinoma, received radical operation from Jan.
  • In addition, the 5-year survival rate was higher in patients with perioperative chemotherapy than in patients without perioperative chemotherapy (47.2% vs. 37.8%, P < 0.05).
  • Univariate analysis showed that perioperative chemotherapy, Borrmann type, tumor size, pathologic type, and pTNM stage were prognostic factors of gastric carcinoma.
  • Multivariate analysis showed that pTNM stage, tumor size, and perioperative chemotherapy were independent prognostic factors of gastric carcinoma.
  • CONCLUSIONS: pTNM stage, tumor size, and perioperative chemotherapy are the most significant factors influencing prognosis of gastric carcinoma patients after radical operation.
  • Perioperative chemotherapy contributes to enhance survival rate of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Prognosis. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890105.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA: S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol; 2004 May;34(5):282-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
  • S-1 is an oral fluoropyrimidine reported to be most active for gastric cancer.
  • However, few studies have documented a complete response (CR) of lung metastasis to S-1 treatment.
  • We describe a 66-year-old woman in whom S-1 induced complete regression of lung metastasis from gastric cancer, that had been refractory to another oral fluoropyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR).
  • After preoperative chemotherapy with a combination of etoposide, adriamycin and cisplatin and with methotrexate plus 5-fluorouracil, the patient underwent a total gastrectomy with lower esophagectomy for advanced diffuse-type gastric cancer with invasion of the esophagus in May 1993.
  • She received postoperative adjuvant chemotherapy with 5'-DFUR (600 mg/day) for 3 years.
  • Chemotherapy with 5'-DFUR was reinitiated after operation, but re-metastasis to the left lung with elevation of the serum carcinoembryonic antigen (CEA) level was diagnosed in June 1999.
  • Treatment with S-1 was started in August.
  • S-1 was given orally in a dose of 100 mg/day for 28 consecutive days, followed by a 14-day recovery; treatment was repeated every 6 weeks.
  • This may be the first report to document a prolonged complete response of lung metastasis from gastric cancer induced by single-agent chemotherapy with S-1.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Antimetabolites, Antineoplastic / pharmacokinetics. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / pharmacokinetics. Pyridines / pharmacokinetics. Stomach Neoplasms / pathology. Tegafur / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Esophagectomy. Female. Floxuridine / administration & dosage. Fluorouracil / blood. Gastrectomy. Humans. Middle Aged. Radiography, Thoracic. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15231865.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


26. Shimoyama S, Imamura K, Katayama A, Hiki N, Shimizu N, Yamaguchi H, Mafune K, Motoi T, Oohashi K, Kaminishi M: [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients]. Gan To Kagaku Ryoho; 2004 Jun;31(6):929-32
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
  • A 46-year-old Japanese female with advanced gastric cancer with positive peritoneal cytology and who was refractory to methotrexate plus 5-FU sequential chemotherapy received low-dose, fractional irinotecan hydrochloride (CPT-11) in combination with cisplatin.
  • The rationale for a low-dose, fractional administration of CPT-11 in combination with cisplatin is the synergistic antitumor activity obtained through the ability of SN-38 to potentiate cisplatin-induced cytotoxicity, as well as the increased therapeutic efficacy of a protracted CPT-11 administration over more intense treatment schedules.
  • As far as we are aware, this case report demonstrates for the first time that a low-dose, fractional administration of CPT-11 with cisplatin can successfully produce a negative change in peritoneal lavage cytology, and potentiates a R0 resection in a 5-FU resistant advanced gastric cancer patient.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Ascitic Fluid / pathology. Cholecystectomy. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Gastrectomy. Humans. Lymph Node Excision. Middle Aged. Neoplasms, Multiple Primary / pathology. Splenectomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222115.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


27. Shikano T, Koshikawa K, Kiriyama K, Wada M, Taniguchi K, Suenaga H: [Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1]. Gan To Kagaku Ryoho; 2006 Jan;33(1):87-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1].
  • The first patient is a 60-year-old man who underwent total gastrectomy and splenectomy for type-3 gastric cancer after neoadjuvant chemotherapy.
  • The second patient is a 69-year-old woman who underwent distal gastrectomy for type-2 gastric cancer and pyloric stenosis after neoadjuvant chemotherapy.
  • No re-growth of peritoneal dissemination was seen for three years or more from treatment with the oral anticancer drug TS-1.
  • Treatment on an outpatient basis, therefore, greatly contributed to their quality of life.
  • We consider TS-1 as a first-line anti-cancer drug for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pyridines / administration & dosage. Stomach Neoplasms / pathology. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Male. Middle Aged. Survivors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410704.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Xu HW, Xu L, Hao JH, Qin CY, Liu H: Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res; 2010 Jan-Feb;38(1):34-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer.
  • This study evaluated the sensitivities of gastric cancer cells to various chemotherapy drugs, and investigated the relationship between the expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) and multidrug resistance.
  • Drug sensitivities were determined using a methyltetrazolium assay: expression levels of P-gp and MRP were measured using immunohistochemistry.
  • On purification culture, gastric cancer cells were found to be most sensitive to cisplatin, mitomycin and adriamycin, moderately sensitive to etoposide and 5-fluorouracil, and less sensitive to homocamptothecin and methotrexate, with sensitivities of 76.7%, 70.0%, 66.7%, 60.0%, 56.7%, 43.3% and 30.0%, respectively.
  • Positive expression for P-gp and MRP in gastric cancer tissues was 41.7% and 29.2%, respectively; coexpression of P-gp and MRP in cancer tissue was 23%.
  • The drug-resistant groups had higher positive expression of P-gp and MRP compared with the drug-sensitive groups.
  • In conclusion, expression of P-gp and MRP seems to be associated with multidrug resistance in gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233511.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein
  •  go-up   go-down


29. Takano S, Honda I, Watanabe S, Soda H, Nagata M, Hoshino I, Takenouchi T, Miyazaki M: PIVKA-II-producing advanced gastric cancer. Int J Clin Oncol; 2004 Aug;9(4):330-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIVKA-II-producing advanced gastric cancer.
  • We describe the case of a 68-year-old man with primary advanced adenocarcinoma of the stomach, who displayed extremely high plasma levels of protein induced by vitamin K antagonist (PIVKA)-II (15 600 mAU/ml) and normal levels of alphafetoprotein (AFP) (4 ng/ml).
  • Ultrasonography and dynamic computed tomography ruled out hepatocellular carcinoma (HCC) or liver metastasis.
  • After preoperative chemotherapy, pancreatico-spleno total gastrectomy with D2 lymphadenectomy was performed.
  • Microscopic examination revealed stomach adenocarcinoma showing various histological types, such as moderately to poorly differentiated mucinous adenocarcinoma, but hepatoid differentiation of gastric adenocarcinoma was not detected.
  • These results indicate that tumor cells from gastric cancer may produce PIVKA-II.
  • Some cases of PIVKA-II- and AFP-producing advanced gastric cancer with liver metastasis have been reported, but this is the first report of gastric cancer without liver metastasis producing PIVKA-II alone.
  • [MeSH-major] Adenocarcinoma / metabolism. Protein Precursors / biosynthesis. Prothrombin / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers / analysis. Digestive System Surgical Procedures. Humans. Male. Neoplasm Staging. Treatment Outcome. alpha-Fetoproteins / analysis. alpha-Fetoproteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15375711.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  • [Number-of-references] 19
  •  go-up   go-down


30. Wang ZH, Guo J, Chen Z, Li CZ, Sheng LJ, Zhou DG, Liu B, Liu J, Wang QC, Zhang EN: [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2008 May;30(5):389-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
  • OBJECTIVE: To evaluate the efficacy and toxicity of a biweekly DOF regimen consisting of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer.
  • METHODS: The biweekly DOF regimen was administered in 37 advanced gastric cancer patients.
  • The time to progression (TTP) was 9.2 months, and median survival time (MST) was 13.7 months.
  • The RRs of 11 chemotherpy-naïve patients and 26 patients pre-treated with chemotherapy were 81.8% and 61.5%, respectively.
  • CONCLUSION: Our preliminary results showed that this biweekly combination regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin is effective and tolerable for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia / chemically induced. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction. Taxoids / administration & dosage. Taxoids / adverse effects. Vomiting / chemically induced. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953843.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Grenacher L, Klauss M: [Computed tomography of pancreatic tumors]. Radiologe; 2009 Feb;49(2):107-23
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computed tomography of pancreatic tumors].
  • Computed tomography (CT) and in particular multi-detector row computed tomography (MDCT), also known as multislice CT (MSCT), is ideally suited for detecting pancreatic tumors because of the high spatial resolution.The method of choice is hydro-CT which involves distension of the stomach and duodenum by administration of 1-1.5 l water as a negative contrast medium under medically induced hypotension by administration of buscopan.
  • After the correct diagnosis of an adenocarcinoma has been made only 20% of all patients are shown to have a surgically resectable disease, but the overall survival rate is significantly higher after resection in combination with a multimodal tumor therapy strategy.
  • The reason is that the correct diagnosis of the resectability of the tumor is one of the main criteria for overall survival of these patients.
  • Currently practically all pancreatic tumors can be detected using MDCT and the detection rate varies between 70% and 100% (most recent literature references give a sensitivity of 89% and specificity up to 99%).
  • MDCT is an ideal tool for the detection of neuroendocrine tumors, metastases and for the differentiation of cystic pancreatic lesions such as pseudocysts, microcystic adenomas or intraductal papillary mucinous neoplasms (IPMN).
  • Moreover MD-CT is an ideal procedure for the differentiation of local tumor stages in patients under neoadjuvant or adjuvant chemotherapy.
  • [MeSH-major] Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Pancreatic Neoplasms / diagnostic imaging. Tomography, Spiral Computed
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / diagnostic imaging. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / diagnostic imaging. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Diagnosis, Differential. Disease-Free Survival. Humans. Neuroendocrine Tumors / diagnostic imaging. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreas / diagnostic imaging. Pancreas / pathology. Pancreatectomy. Pancreatic Pseudocyst / diagnostic imaging. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2006 Nov;79(947):880-7 [16822803.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Pancreatology. 2008;8(3):236-51 [18497542.001]
  • [Cites] Radiologe. 2003 Apr;43(4):293-300 [12721645.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Pancreas. 2005 Apr;30(3):218-22 [15782097.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1471-84 [16284129.001]
  • [Cites] Eur Radiol. 2004 Jul;14 (7):1188-95 [15083335.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Radiology. 2000 Jul;216(1):163-71 [10887243.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):149-56 [12541123.001]
  • [Cites] Radiologe. 2008 Aug;48(8):752-63 [18633589.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):459-64 [9242754.001]
  • [Cites] Eur J Radiol. 2007 Jun;62(3):371-7 [17433598.001]
  • [Cites] Chirurg. 2003 Mar;74(3):202-7 [12647076.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Histopathology. 2008 Apr;52(5):539-51 [17903202.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Radiologe. 1996 May;36(5):397-405 [8778924.001]
  • [Cites] J Magn Reson Imaging. 2007 Jul;26(1):86-93 [17659551.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Apr 13;132(15):813-7 [17427092.001]
  • [Cites] Arch Surg. 1998 Jan;133(1):61-5 [9438761.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):75-85 [16372157.001]
  • [Cites] Pancreatology. 2008;8(2):199-203 [18434757.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Pancreas. 2006 Aug;33(2):111-8 [16868475.001]
  • [Cites] JOP. 2007 Mar 10;8(2):214-22 [17356246.001]
  • [Cites] Pancreatology. 2008;8(2):135-41 [18382099.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Pancreatology. 2008;8(2):204-10 [18434758.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Rofo. 1998 Mar;168(3):211-6 [9551105.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] AJR Am J Roentgenol. 1990 Nov;155(5):995-6 [2120971.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):233-43 [10481116.001]
  • [Cites] Eur Radiol. 2007 Mar;17(3):638-49 [17021700.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Pancreatology. 2009;9(5):621-30 [19657217.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Radiology. 1993 Mar;186(3):799-802 [8381551.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19137277.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 71
  •  go-up   go-down


32. Kleikamp S, Böhm M, Frosch P, Brinkmeier T: [Acanthosis nigricans, papillomatosis mucosae and "tripe palms" in a patient with metastasized gastric carcinoma]. Dtsch Med Wochenschr; 2006 May 26;131(21):1209-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acanthosis nigricans, papillomatosis mucosae and "tripe palms" in a patient with metastasized gastric carcinoma].
  • [Transliterated title] Acanthosis nigricans, Papillomatosis mucosae und "tripe palms" bei einem Patienten mit metastasiertem Magenkarzinom.
  • Gastroscopic findings were suspicious of adenocarcinoma of the stomach: it was classified histologically as a signet-ring cell, non-mucinous adenocarcinoma.
  • At the time of diagnosis the tumor had already metastasized to perigastric and peripancreatic lymph nodes with peritoneal carcinosis.
  • TREATMENT AND COURSE: Since a curative resection was impossible a gastrojejunostomy was carried out.
  • After this the patient received several courses of chemotherapy according to different schemes.
  • Serum tumor marker levels and cutaneous signs regressed several times.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Skin Diseases / etiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Acanthosis Nigricans / diagnosis. Acanthosis Nigricans / etiology. Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Fatal Outcome. Humans. Immunohistochemistry. Keratoderma, Palmoplantar / diagnosis. Keratoderma, Palmoplantar / etiology. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms / diagnosis. Mouth Neoplasms / etiology. Obesity / complications. Papilloma / diagnosis. Papilloma / etiology. Peritoneal Neoplasms / secondary. Receptor, Melanocortin, Type 1 / analysis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721709.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / CA-72-4 antigen; 0 / Carcinoembryonic Antigen; 0 / Receptor, Melanocortin, Type 1
  •  go-up   go-down


33. Xue YW, Wei YZ: The relationship of prognosis to surgery and pathologic characteristics of stage IV (M0) gastric cancer patients. Chin J Cancer; 2010 Apr;29(4):355-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of prognosis to surgery and pathologic characteristics of stage IV (M0) gastric cancer patients.
  • BACKGROUND AND OBJECTIVE: The proportion of stage IV gastric cancer in the whole gastric cancer population in China is still high.
  • This study was to investigate the surgery and pathologic characteristic and prognostic factors of stage IV (M0) gastric cancer.
  • METHODS: Clinical data of 630 patients with pathologically confirmed stage IV (M0) gastric cancer treated at the affiliated Tumor Hospital of Harbin Medical University between January 1993 and August 2004 were analyzed using Cox proportional hazard model.
  • Univariate analysis showed that Borrmann type, lymphatic metastasis, organ involvement, tumor location, tumor size, pathologic type, radical excision and other organ excision were significant prognostic factors affecting 1-year survival rate (P < 0.05); Borrmann type, lymphatic metastasis, organ involvement, pathologic type and radical excision affected 3-year survival rate (P < 0.05); only organ involvement and pathologic type affected 5-year survival rate (P < 0.05).
  • Multivariate analysis showed that pathologic type was independent prognostic factor for poor survival.
  • CONCLUSIONS: Radical resection and combined organ resection could prolong the survival of stage IV (M0) gastric cancer patients.
  • Chemotherapy, radiotherapy and targeted therapy should be considered for individual therapeutic regimen.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346207.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


34. Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M, Hirakawa K, Ohta T: Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol; 2009 Jun;34(6):1573-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin.
  • Angiotensin II is a main effector peptide in renin-angiotensin system, acting as a growth promoter via angiotensin II type 1 (AT1) receptor.
  • The present study examined intrinsic angiotensin II generating system in gastric cancer and potential roles of angiotensin II in cellular proliferation and survival.
  • The expression of AT1 receptor was examined in gastric cancer cell lines and tissues.
  • In addition, we measured angiotensin II concentration in tissues from twenty gastric cancer and corresponding normal region using the florisil method.
  • In vitro, we investigated the potential roles of angiotensin II in cellular proliferation and cell survival in cultured human gastric cancer cell line.
  • AT1 receptor protein was expressed in gastric cancer cell lines and tissues.
  • Angiotensin II stimulates the cell proliferation in the AT1 receptor-positive OCUM2MD3 gastric cancer cell line and this proliferative effect of angiotensin II was inhibited by a specific AT1 receptor antagonist, candesartan.
  • Candesartan significantly prolonged survival time in a mouse model of peritoneal carcinomatosis compared with control group (p=0.0.197, log-rank test).
  • Our data provide in vivo evidence of intrinsic angiotensin II generating system in gastric cancer and indicate locally formed angiotensin II is involved in cellular proliferation and survival.
  • [MeSH-major] Angiotensin II / biosynthesis. Microtubule-Associated Proteins / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. NF-kappa B / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Angiotensin II Type 1 Receptor Blockers / pharmacology. Animals. Apoptosis / drug effects. Benzimidazoles / pharmacology. Blotting, Western. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / secondary. Case-Control Studies. Cell Proliferation / drug effects. Disease Progression. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Receptor, Angiotensin, Type 1 / chemistry. Receptor, Angiotensin, Type 1 / drug effects. Receptor, Angiotensin, Type 1 / metabolism. Stomach / metabolism. Stomach / pathology. Survival Rate. Tetrazoles / pharmacology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424575.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / BIRC5 protein, human; 0 / Benzimidazoles; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Receptor, Angiotensin, Type 1; 0 / Tetrazoles; 11128-99-7 / Angiotensin II; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; S8Q36MD2XX / candesartan
  •  go-up   go-down


35. Sugiyama T, Kumagai S, Hatayama S: [Treatments of epithelial ovarian cancer by histologic subtype]. Gan To Kagaku Ryoho; 2009 Feb;36(2):187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatments of epithelial ovarian cancer by histologic subtype].
  • Recent molecular studies support the hypothesis that clear cell carcinoma and mucinous adenocarcinoma are refractory cancers that are biologically distinct from serous adenocarcinoma.
  • Treatment of these cancers has not yet been adequately tested, so separate clinical trials are needed for each type.
  • Clear cell carcinoma and mucinous adenocarcinoma are less sensitive to a TC regimen than serous adenocarcinoma, and an international randomized trial for clear cell carcinoma is now underway(GCIG/JGOG3017).
  • Targeted therapy is attractive for chemoresistant clear cell carcinoma, thus VEGFR inhibitor(sunitinib), PDGFR inhibitor(sorafenib), m-TOR inhibitor (temsirolimus), and monoclonal antibody(bevacizumab)are being evaluated.
  • Mucinous adenocarcinoma often shows CK20- and CEA-positive patterns in immunohistochemistry, and furthermore, p53-negative and K-ras-positive in molecular markers, which suggests that mucinous adenocarcinoma resembles colorectal, stomach, and pancreas cancers more than serous ovarian adenocarcinoma.
  • For refractory cancers, molecular biology-based, cross- organ treatment with cytotoxic/cytostatic agents is needed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans. Survival Rate


36. Liu Y, Wang R, Qiu GQ, Nan KJ, Sun XC: Inhibitory effect of fuzheng yiliuyin in combination with chemotherapeutics on human gastric carcinoma cell strain. World J Gastroenterol; 2006 Jul 7;12(25):4071-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of fuzheng yiliuyin in combination with chemotherapeutics on human gastric carcinoma cell strain.
  • AIM: To study the inhibitory effects of fuzheng yiliuyin (Decoction for Suppressing Tumors by Strengthening the Body Resistance) in combination with chemotherapeutics on human gastric carcinoma cell strain.
  • METHODS: Fuzheng yiliuyin (ZY) combined with various kinds of chemotherapeutics was put into two kinds of cultivated human gastric carcinoma cell strains, then its inhibitory effects on human gastric carcinoma cell strains were determined by the MTT method.
  • Flow cytometer was used to assay the apoptosis rate, and the ultrastructure of gastric carcinoma cells was observed under transmission electron microscope.
  • RESULTS: Obvious apoptosis was seen in gastric carcinoma cells after treatment with ZY for 72 h.
  • ZY and chemical drugs had synergistic inhibition effects on the cultivated gastric carcinoma cells, but the effects were different on various cell strains.
  • ZY combined with fluorouracil, etoposide and cisplatin (EFP) chemotherapeutics had better inhibitory effects on SGC-7901, while ZY combined with EFP or with DDP chemotherapeutics had better inhibitory effects than other drugs on MGC-803.
  • CONCLUSION: ZY induces apoptosis and inhibits the growth of gastric carcinoma cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Drugs, Chinese Herbal / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Cell Line, Tumor. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2001 Jun;18(6):1227-32 [11351255.001]
  • [Cites] J Tradit Chin Med. 2005 Mar;25(1):21-2 [15889516.001]
  • [Cites] J Chemother. 2002 Dec;14(6):623-6 [12583555.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Feb;22(2):104-6 [12585144.001]
  • [Cites] Di Yi Jun Yi Da Xue Xue Bao. 2005 Oct;25(10):1308-11 [16234118.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Feb;2(2):98-107 [16264882.001]
  • [Cites] Am J Chin Med. 2003;31(3):363-77 [12943168.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jul;22(7):515-7 [12592686.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):203-9 [12714898.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):423-9 [12836016.001]
  • [Cites] Cancer Lett. 2004 Sep 30;213(2):213-21 [15327837.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):192-4 [15339559.001]
  • [Cites] Cancer Biol Ther. 2005 Feb;4(2):242-7 [15846068.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):931-7 [15868930.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2005 May;3(3):195-8 [15885167.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):40-3 [12508348.001]
  • (PMID = 16810762.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / fuzheng yiliuyin
  • [Other-IDs] NLM/ PMC4087724
  •  go-up   go-down






Advertisement